FDA Approves Eucrisa for Eczema

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

Eczema, also known as atopic dermatitis, is a skin condition that affects nearly 18 million Americans. Worldwide, eczema affects 15-20% of children and 1-3% of adults.

The signs and symptoms of eczema differ from person-to-person, but may include symptoms like dry sensitive skin, itchiness, dark colored patches of skin, or areas of swelling.

The FDA recently approved a new topical ointment for the treatment of mild to moderate eczema, called Eucrisa!

What is Eucrisa indicated for?

Eucrisa is a phosphodiesterase 4 inhibitor (PDE-4) indicated for the treatment of mild to moderate atopic dermatitis (eczema) in patients 2 years of age and older.

What is eczema?

Eczema is a medical condition in which patches of skin become rough and inflamed, with blisters that cause itching and bleeding. Sometimes symptoms can result from a reaction to an irritant, but more typically, symptoms have no external cause.

Eczema is caused by genetic, immune and environmental factors. Eczema triggers include a family history of eczema, immune system overreaction, allergies, and asthma.

Is there an advantage to using Eucrisa?

Yes. Eucrisa is the 1st and only non-steroidal topical ointment for the treatment of eczema.

Eucrisa will be available as an ointment in a strength of 2%. Eucrisa is to be applied topically in a thin layer twice daily to the affected areas.

What are the common side-effects associated with Eucrisa?

The most common side effects include application site pain such as burning and stinging

For more information, you can read the press announcement here.

Filed under